Results 111 to 120 of about 307,775 (306)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Advancing through the blood-brain barrier: mechanisms, challenges and drug delivery strategies

ADMET and DMPK
Background and purpose: The delivery of therapeutics to the central nervous system (CNS) remains a major challenge due to the restrictive nature of the blood-brain barrier (BBB), a key evolutionary feature that preserves brain homeostasis.
Ronny Vargas, Noelia Martinez-Martinez, Catalina Lizano-Barrantes, Jorge Andrés Pacheco-Molina, Encarna García-Montoya, María Pilar Pérez-Lozano, Josep María Suñe-Negre, Carlos Suñe, Marc Suñe-Pou   +8 more
doaj   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Chemotherapeutic Drug Delivery Nanoplatform Development: From Physicochemical to Preclinical Evaluation

International Journal of Molecular Sciences
Through this study, the synergistic behavior of small-molecular-weight, amphiphilic surfactant molecules and the triblock copolymer Pluronic 188 was extensively evaluated based on their ability to formulate nanocarriers with novel properties for the delivery of class II and IV (biopharmaceutical classification system) chemotherapeutic compounds.
Orestis Kontogiannis, Dimitrios Selianitis, Konstantinos Palikaras, Natassa Pippa, Stergios Pispas, Efstathios Efstathopoulos, Maria Gazouli   +6 more
openaire   +3 more sources

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

Mechanism-based Preclinical Approaches for the Evaluation of Drug-Drug Interactions.

Drug Metabolism and Pharmacokinetics, 2000
Pharmacokinetic drug-drug interactions (PDDI), in which the pharmacokinetic clearance of one drug is altered by a co-administered drug, can be divided mechanistically into two general categories: 1. inhibitory PDDI, the inhibition of the metabolic clearance of one drug by a co-administered drug; and 2.
openaire   +2 more sources

Preclinical Pharmacokinetics, ADME, and Drug-Drug Interaction Evaluation of S024, a Novel p38/MK2 Inhibitor for Rheumatoid Arthritis

Drug Design, Development and Therapy
Qianlei Ye,1,2,* Wei Xing,2,* Xuefeng Hu,2 Wenjuan Liu,2 Jigang Wu,2 Hailan Huang,2 Ying Xiao,2 Yanjun Hong1 1School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen, People’s Republic of China; 2Shenzhen Salubris ...
Ye Q, Xing W, Hu X, Liu W, Wu J, Huang H, Xiao Y, Hong Y   +7 more
doaj  

Research Progress on Quality Evaluation of Drug-Loaded Contact Lenses

Zhongguo yiliao qixie zazhi
As a novel ocular drug delivery system, drug-loaded contact lenses have overcome the limitations of traditional ophthalmic drug formulations and possess characteristics such as high bioavailability, low toxicity and side effects, and prolonged effective ...
Zhuoyu SONG, Zhenqi LIU, Jianfeng SHI, Yuanli HUANG, Qianqian HAN, Chunmeng SUN   +5 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Multitask CapsNet: An Imbalanced Data Deep Learning Method for Predicting Toxicants

ACS Omega, 2021
Yiwei Wang, Binyou Wang, Jie Jiang, Jianmin Guo, Jia Lai, Xiao-Yuan Lian, Jianming Wu   +6 more
doaj   +1 more source